Rapport Therapeutics annual free cash flow
2023
2024
2025
Rapport Therapeutics Free Cash Flow (FCF) History (RAPP)
Rapport Therapeutics reported −$88.1M in free cash flow for fiscal 2025, a decrease of $20.9M from the previous fiscal year.
View full Rapport Therapeutics company overviewRapport Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$88.1M | −$20.9M | — | — |
| 2024 | 2024-12-31 | −$67.2M | −$38.4M | — | — |
| 2023 | 2023-12-31 | −$28.8M | — | — | — |
Rapport Therapeutics quarterly free cash flow
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$41.5M | −$16.4M | — | — |
| Q1 2026 | 2026-03-31 | −$13.1M | $7.4M | — | −65.73% |
| Q4 2025 | 2025-12-31 | −$24.9M | −$10.2M | — | — |
| Q3 2025 | 2025-09-30 | −$17.6M | −$1.0M | — | — |
| Q2 2025 | 2025-06-30 | −$25.1M | −$7.8M | — | — |
| Q1 2025 | 2025-03-31 | −$20.5M | −$1.8M | — | — |
| Q4 2024 | 2024-12-31 | −$14.7M | — | — | — |
| Q3 2024 | 2024-09-30 | −$16.6M | −$11.1M | — | — |
| Q2 2024 | 2024-06-30 | −$17.3M | — | — | — |
| Q1 2024 | 2024-03-31 | −$18.7M | — | — | — |
| Q3 2023 | 2023-09-30 | −$5.5M | — | — | — |
Rapport Therapeutics free cash flow growth trends
Rapport Therapeutics's latest reported quarter, Q2 2026, generated −$41.5M in free cash flow, a decrease of $16.4M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Rapport Therapeutics source filings ↗Community posts
Rapport’s bipolar-mania study meets its primary endpoint in Phase 2
Rapport Therapeutics ($RAPP) reported positive topline results from a randomized, double-blind Phase 2 trial of RAP-219 in 253 adults with acute mania associated with bipolar I disorder. After three weeks, the treatment group improved by 15 ...
